^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TGF-β R2 kinase inhibitor

    Related drugs:
    16d
    Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases (clinicaltrials.gov)
    P3, N=332, Not yet recruiting, Peking University
    New P3 trial
    |
    Tyvyt (sintilimab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    23d
    From M7824 to SHR-1701: lessons for dual PD-L1/TGF-β targeting. (PubMed, J Immunother Cancer)
    We highlight that TGF-β-driven immune suppression and immune exclusion are often spatially organized within stromal niches, vary across indications, and are not always the dominant barrier even when PD-L1 is expressed. SHR-1701's approval provides proof of principle in a defined context and supports mechanism-aligned development using biomarker-driven selection, rational combinations and sequencing, and pharmacodynamic endpoints that directly test these assumptions.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824) • retlirafusp alfa (SHR-1701)
    23d
    Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study (clinicaltrials.gov)
    P2, N=44, Active, not recruiting, Harbin Medical University
    New P2 trial
    |
    capecitabine • oxaliplatin • retlirafusp alfa (SHR-1701)
    1m
    GOLPH3 promotes papillary thyroid carcinoma by regulating the TGF-β signaling pathway. (PubMed, Mol Genet Genomics)
    However, as an inhibitor of this pathway, LY2109761 could reverse the effects induced by GOLPH3 overexpression. Collectively, these findings establish GOLPH3 as a critical driver of PTC malignancy through TGF-β pathway activation, providing a mechanistic link between Golgi function and cancer signaling. This work not only advances our understanding of PTC pathogenesis but also identifies GOLPH3 as a potential therapeutic target for aggressive PTC, offering a paradigm for exploring Golgi-associated proteins in endocrine malignancies.
    Journal
    |
    CDH1 (Cadherin 1) • TGFB1 (Transforming Growth Factor Beta 1) • CDH2 (Cadherin 2) • SNAI1 (Snail Family Transcriptional Repressor 1) • SMAD2 (SMAD Family Member 2) • SMAD3 (SMAD Family Member 3)
    |
    LY2109761
    1m
    Neoadjuvant retlirafusp alfa (anti-PD-L1/TGF-β bifunctional fusion protein) with or without chemotherapy in unresectable stage III non-small cell lung cancer: updated results from the phase 2 TRAILBLAZER trial. (PubMed, Signal Transduct Target Ther)
    Patients who underwent surgery after induction treatment achieved clinically meaningful survival gains. Our findings support the use of neoadjuvant immunotherapy with a response-adapted surgical strategy as a promising approach for unresectable stage III NSCLC.
    Clinical • P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression • PD-L1 overexpression
    |
    retlirafusp alfa (SHR-1701)
    1m
    SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage III Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, Fudan University
    New P2 trial
    |
    retlirafusp alfa (SHR-1701)
    2ms
    Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Tang-Du Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)
    2ms
    RA-A-NP: Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Henan Cancer Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiTan (rivoceranib) • albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)
    2ms
    A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    oxaliplatin • retlirafusp alfa (SHR-1701)
    2ms
    Optimal First-line Immune-related Therapy Selection for Advanced Gastric Cancer: A Systematic Review and Network Meta-analysis. (PubMed, J Gastrointest Cancer)
    Dual-target ICI-chemo appears to be the most effective first-line strategy for AGC based on current indirect evidence, surpassing single ICI-chemo and dual ICI-based regimens. These findings support personalized therapy selection but await confirmation by head‑to‑head trials. Future studies should address CPS < 1 and explore optimized combinations to enhance outcomes.
    Clinical • Retrospective data • Review • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    retlirafusp alfa (SHR-1701)
    2ms
    Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC (clinicaltrials.gov)
    P2, N=78, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P2 trial
    |
    retlirafusp alfa (SHR-1701) • AiRuiLi (adebrelimab)
    3ms
    Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III NSCLC (Phase 2) (clinicaltrials.gov)
    P2, N=18, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    EGFR mutation
    |
    albumin-bound paclitaxel • retlirafusp alfa (SHR-1701)